Biomarin Pharmaceutical Inc
NASDAQ: BMRN
$70.69
-$0.72 (-1.0%)
Closing Price on September 20, 2024
BMRN Articles
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the highest upside to their target...
Published:
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this year.
Published:
Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going forward but can stay intact. They think the fundamental backdrop is...
Published:
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
Published:
ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech...
Published:
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company...
Published:
Last Updated:
ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a U.S. Food and Drug Administration (FDA) approval or a life-saving capital raise is the difference...
Published:
Last Updated:
Investors and traders seem to be constantly looking for fresh research ideas that will lead to higher income or more profits. 24/7 Wall St. reviews many research calls each day to find great ideas...
Published:
Last Updated:
ThinkstockFriday’s nonfarm payroll number was a pleasant surprise. However, for real growth to return we need to consistently add 250,000 jobs per month. Our economy is sluggish at best, and...
Published:
Last Updated:
ThinkstockMuch of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best known stocks from the S&P 500. These names are recognizable to investors...
Published:
Last Updated:
via Wikimedia CommonsBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is surging on news that a drug met its primary endpoint and that it will seek approval in early 2013. The company’s Phase III...
Published:
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Monday morning. Amazon.com Inc. (NASDAQ: AMZN) reiterated Buy with $264...
Published:
Last Updated:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is...
Published:
Last Updated: